StockData
Lifevantage Corp logo

Lifevantage Corp (LFVN) company profile

LFVNNasdaqPharmaceutical PreparationsFiscal year ends December 31
Số liệu tài chính tới Q4 năm tài chính 2026, quý kết thúc ngày Jun 30, 2026Last filing: 10-Q on Nov 9, 2026Score 20/3044% below fair value
$4.78+0.01 (+0.21%)

Close on Nov 17, 2026Market cap $59.88MP/E 12.0Yield 3.87%

About Lifevantage

Pharmaceutical Preparations, SIC 2834

LifeVantage Corporation engages in the identification, research, development, formulation, and sale of advanced nutrigenomic activators, dietary supplements, weight management and gut health products, nootropics, and personal care items. Its principal offerings include Protandim dietary supplements, TrueScience skin and hair care products, the MindBody GLP-1 and Rise AM & Reset PM systems, AXIO drink mixes, and Petandim companion pet supplements. The company distributes its products through a network marketing direct sales model, utilizing independent consultants as well as direct consumer transactions and subscription programs.

The company operates internationally, commercializing products across North America, Europe, Asia, and Australasia. Its geographic markets include the United States, Mexico, Canada, Japan, Taiwan, Thailand, Australia, New Zealand, the United Kingdom, the Netherlands, Germany, Austria, Spain, Ireland, Belgium, Iceland, and Portugal. LifeVantage also sells products into several other countries exclusively for personal consumption. The company maintains its corporate headquarters in Lehi, Utah.

Summary of the business section of Lifevantage's latest annual report, written by StockData.

Company profile

Company

Legal name
Lifevantage Corp
Founded
1988
Headquarters
Lehi, UT
Address
3300 Triumph Blvd, Suite 700 84043
Phone
(801) 432-9000
Employees
223, Jun 30, 2026
Industry
Pharmaceutical Preparations
Fiscal year ends
December 31
Auditor
Deloitte & Touche LLP, Salt Lake City, Utah

Stock & identifiers

Ticker
LFVN
Exchange
Nasdaq
IPO date
Apr 7, 1994
Shares outstanding
13M, Aug 26, 2026
Public float
$63.70M, Dec 31, 2025
Filer category
Accelerated filer<br>Smaller reporting company
Stock splits
1-for-7 reverse, Oct 19, 2015; 1-for-68 reverse, Oct 5, 2004
SEC CIK
849146
CUSIP
53222K205
ISIN
US53222K2050
FIGI
BBG000CDJHR0
Share class FIGI
BBG001S6TDX7
LEI
5493001Z5YYT109QZ980
EIN
90-0224471

Executives and directors

Officers and directors who filed ownership reports (Forms 3, 4, 5) in the last two years

NamePositionShares owned
Terrence MooreheadPresident and CEO, Director501,879
Steven R. FifePresident and CEO, Director735,471
Carl AureChief Financial Officer191,784
Kristen CunninghamChief Sales Officer152,375
Alissa NeufeldGeneral Counsel112,744
Todd ThompsonChief Information Officer50,729
Julie BoysterChief Marketing Officer150,088
Michael A. BeindorffDirector82,709
Judd DaytonDirector847,572
Darwin LewisDirector156,132
Raymond B. GreerDirector130,707
Rajendran AnbalaganDirector41,887
Cynthia LathamDirector64,879
Garry Paul MauroDirector257,821

CEO pay and shareholder return

Pay versus performance table from the proxy statement

Fiscal yearCEO total payCEO pay actually paidOther executives (avg)Value of $100 investedPeer group
FY2026
Michael Beindorff
$233.00K$178.54K$786.05K$49–
FY2026
Steven RFife
$2.19M-$218.72K$786.05K$49–
FY2025
Michael Beindorff
$0$0$1.01M$206–
FY2025
Steven RFife
$2.82M$7.47M$1.01M$206–
FY2024
Michael Beindorff
$0$0$703.97K$160–
FY2024
Steven RFife
$2.30M$3.05M$703.97K$160–

“Actually paid” adjusts reported pay for changes in the value of equity awards. Shareholder return assumes $100 invested at the start of the measurement period, as disclosed by the company.

Executive compensation, fiscal 2026

Summary compensation table from the latest proxy statement

ExecutiveSalaryStock awardsIncentive payOtherTotalvs. prior year
Michael Beindorff
Interim President and Chief Executive Officer
$141.67K$91.33K––$233.00K–
Steven R. Fife
Former President and Chief Executive Officer
$512.22K$1.56M$32.08K$85.78K$2.19M-22%
Kristen Cunningham
Chief Sales Officer
$340.00K$399.19K$13.60K$62.65K$815.44K–
Carl Aure
Chief Financial Officer
$367.50K$331.03K$18.50K$39.63K$756.66K–

Stock and option awards are grant-date fair values, not realized pay. “Other” includes pension value changes and all other compensation. Source proxy statement.

Employees

Headcount reported in annual reports

“As of June 30, 2026, we had 223 employees, 209 of which were full-time employees.”

Corporate history

Events identified from SEC filings

DateEventDetails
Aug 31, 2023ListingRegistration of securities on an exchange (Form 8-A)
Apr 17, 2023Auditor changeChange in certifying accountant (8-K Item 4.01)
Feb 16, 2023Auditor changeChange in certifying accountant (8-K Item 4.01)
Nov 18, 2016Listing noticeNotice of delisting or failure to satisfy a listing rule (8-K Item 3.01)
Nov 10, 2016Late filingNotification of late filing
Sep 30, 2016Listing noticeNotice of delisting or failure to satisfy a listing rule (8-K Item 3.01)
Sep 13, 2016Late filingNotification of late filing
Jul 13, 2016Auditor changeChange in certifying accountant (8-K Item 4.01)
Apr 13, 2016Auditor changeChange in certifying accountant (8-K Item 4.01)
Oct 6, 2015Listing noticeNotice of delisting or failure to satisfy a listing rule (8-K Item 3.01)
Apr 2, 2015Listing noticeNotice of delisting or failure to satisfy a listing rule (8-K Item 3.01)
Sep 11, 2012ListingRegistration of securities on an exchange (Form 8-A)
Feb 8, 2008Auditor changeChange in certifying accountant (8-K Item 4.01)
Jan 30, 2008Auditor changeChange in certifying accountant (8-K Item 4.01)
Nov 14, 2007Late filingNotification of late filing
Sep 28, 2007Late filingNotification of late filing
Dec 6, 2006Name changeName changed from LIFELINE THERAPEUTICS, INC. to Lifevantage Corp
Sep 29, 2005Late filingNotification of late filing
May 17, 2005Late filingNotification of late filing
Feb 15, 2005Late filingNotification of late filing
Jan 4, 2005Auditor changeChange in certifying accountant (8-K Item 4.01)
Nov 10, 2004Acquisition / saleCompletion of acquisition or disposition of assets (8-K Item 2.01)
Oct 28, 2004Acquisition / saleCompletion of acquisition or disposition of assets (8-K Item 2.01)
Sep 28, 2004Name changeName changed from YAAK RIVER RESOURCES INC to LIFELINE THERAPEUTICS, INC.
Aug 12, 2004Late filingNotification of late filing
Mar 31, 2004Late filingNotification of late filing
May 14, 2003Late filingNotification of late filing
Mar 31, 2003Late filingNotification of late filing
Nov 15, 2002Late filingNotification of late filing
Aug 15, 2002Late filingNotification of late filing

See a number that looks wrong?